Trending...
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
SAN JOSE, Calif. - Californer -- Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921 is a small molecule drug available in oral formulation.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
- Luxury Auto Detailing Brings High-End Mobile Car Care to Cherry Valley and Surrounding Areas
- Transgender Visual Artist Debuts New Work
- Stay Cool All Day With BGMgirl Drawstring Half Wigs
- California: Governor Newsom proclaims Independence Day 2025
- Gundam GQuuuuuuX Takes Center Stage at Anime Expo 2025
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
Source: Biomed Industries Inc.
Filed Under: Medical
0 Comments
Latest on The Californer
- Fireworks, fun, and safety: California preps for the holiday weekend
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV
- Legacy vs. Legacy Gala: Celebrating the Past, Powering the Future of the L.A. Watts Summer Games
- Orion Retreats: Pioneering the Future of Conscious Leadership and Luxury Wellness Tourism
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- California: Governor Newsom statement on passage of Trump's "Big, Beautiful Betrayal"
- From Barrio to Transgender Pioneer: Chapter 12 of A Letter to Pawtone
- MERCURY INSURANCE NAMED ONE OF AMERICA'S GREATEST WORKPLACES FOR PARENTS & FAMILIES AND FINANCIAL SERVICES BY NEWSWEEK
- Ahead of Holiday weekend, Californians see lowest July prices at the pump in 3 years
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- Porta Potty USA Expands its Convenient Portable Restroom Rental Services Business in Montana Area
- Countrywide Fence Rental Expands its Temporary Fence Rental Business in Minnesota Area
- A Shepherd's Legacy: Honoring the Life and Impact of Pastor Ross Reinman
- California: Here's how President Trump's tax cuts for the ultra-rich will hurt YOU
- New Media Film Festival Announces Winners
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives